Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Regeneron Pharmaceuticals (NQ: REGN )

753.03 +3.52 (+0.47%)
Streaming Delayed Price Updated: 4:00 PM EST, Nov 26, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Regeneron Pharmaceuticals

< Previous 1 2
...
17 18 19 20 21 22 23 24 25
...
42 43 Next >
Regeneron Pharmaceuticals Unusual Options Activity For April 05
Via Benzinga
Regeneron to Report First Quarter 2023 Financial and Operating Results and Host Conference Call and Webcast on May 4, 2023
From Regeneron Pharmaceuticals, Inc.
Via GlobeNewswire
Large Cap Biopharmaceuticals Q1 2023: In This Bullish Run Biotech Lags
It was very difficult to make money in Q1 trading healthcare or biotech ETFs because of the sharp rally in other sectors. Nonetheless, there were two big winners. 
Via Talk Markets
10 Health Care Stocks With Whale Alerts In Today's Session
Via Benzinga
$100 Invested In This Stock 5 Years Ago Would Be Worth $200 Today
Via Benzinga
JP Morgan Maintains Overweight Rating for Regeneron Pharmaceuticals: Here's What You Need To Know
Via Benzinga
Regeneron Pharmaceuticals Unusual Options Activity For March 28
Via Benzinga
Analyst Ratings for Regeneron Pharmaceuticals
Via Benzinga
NVIDIA To Rally Around 18%? Here Are 10 Other Analyst Forecasts For Friday
Benchmark cut the price target for CuriosityStream Inc. (NASDAQ: CURI) from $8 to $4. Benchmark analyst Daniel Kurnos maintained a Buy rating. CuriosityStream shares dropped 22.5% to $1.24 in... 
Via Benzinga
Is This Pharma Duo on the Brink of Another Billion-Dollar Opportunity?
Sanofi and Regeneron's top-selling drug could soon be approved to treat yet another disease. 
Via The Motley Fool
Libtayo® (cemiplimab) in Combination with Chemotherapy Approved by European Commission for the First-line Treatment of Advanced PD-L1 Positive Non-small Cell Lung Cancer (NSCLC)
From Regeneron Pharmaceuticals, Inc.
Via GlobeNewswire
Regeneron Pharmaceuticals, Hess And 1 Of World's Biggest Bank: CNBC's 'Final Trades'
On CNBC’s "Halftime Report Final Trades," Bryn Talkington of Requisite Capital Management said she is sticking with Regeneron Pharmaceuticals, Inc. 
Via Benzinga
Baird Maintains Neutral Rating for Regeneron Pharmaceuticals: Here's What You Need To Know
Via Benzinga
Regeneron Pharmaceuticals (NASDAQ: REGN) is a Leading Gainer in 3/23 Morning Trading
Via Investor Brand Network
Why Shares of Regeneron Are Rising Thursday
Regeneron released positive phase 3 trial results for its therapy Dupixent. 
Via The Motley Fool
Sonoma Biotherapeutics and Regeneron Announce Collaboration to Discover, Develop and Commercialize Treg Cell Therapies for Autoimmune Diseases
From Sonoma Biotherapeutics, Inc.
Via Business Wire
Regeneron and Sonoma Biotherapeutics Announce Collaboration to Discover, Develop and Commercialize Treg Cell Therapies for Autoimmune Diseases
Sonoma Biotherapeutics to receive $75 million upfront, inclusive of $45 million cash and $30 million equity investment; potential for an additional $45 million development milestone payment 
From Regeneron Pharmaceuticals, Inc.
Via GlobeNewswire
(REGN) - Analyzing Regeneron Pharmaceuticals's Short Interest
Via Benzinga
Sanofi, Regeneron Shares Pop On Big News About COPD Treatment
Sanofi and Regeneron bolted higher on news about their jointly developed COPD medication Dupixent. Analysts say sales may hit $20 billion within a decade. 
Via MarketBeat
UNITY Biotechnology's Wet AMD Candidate Flunks On Non-Inferiority Threshold Compared To Regeneron's Drug
UNITY Biotechnology Inc (NASDAQ: UBX) announced results from Part A of the Phase 2 ENVISION study of UBX1325 in patients with wet age-related macular degeneration (AMD) who were not achieving optimum... 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For March 27, 2023
Via Benzinga
Pinterest To Rally Over 27%? Here Are 10 Other Analyst Forecasts For Monday
UBS cut the price target for DISH Network Corporation (NASDAQ: DISH) from $27 to $10. UBS analyst John Hodulik downgraded the stock from Buy to Neutral. DISH Network shares fell 2.1% to $8.57 in... 
Via Benzinga
Could This Label Expansion Be a Growth Catalyst for Sanofi Stock?
Sanofi and Regeneron's mega-blockbuster drug could soon be approved in the U.S. for yet another indication. 
Via The Motley Fool
Wall Street Has High Hopes for These 2 Nasdaq Stocks
Even in choppy markets, there are smart investments you can make. 
Via The Motley Fool
Stock Market Split As Fed Hikes Rates, Banks Keep Tumbling; Nvidia, On Holding In Focus: Weekly Review
The major indexes showed volatile, divergent action. 
Via Investor's Business Daily
Benzinga's Top Ratings Upgrades, Downgrades For March 24, 2023
Via Benzinga
Regeneron Pharmaceuticals Analysts React To Drug Trial Results: Why Whales Are Diving In
Regeneron Pharmaceuticals Inc (NASDAQ: REGN) announced the Phase 3 trial of Dupixent (dupilumab), developed with Sanofi (NASDAQ: SNY), for uncontrolled chronic obstructive pulmonary disease (COPD) met... 
Via Benzinga
Regeneron Pharmaceuticals Options Traders Betting On Stock Falling This Much By April Expiration
Sanofi (NASDAQ: SNY) and Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) shares surged on Thursday after the companies announced primary and all key secondary endpoints were met in a Phase 3 trial... 
Via Benzinga
US Stocks On Track For Weak Start Friday Amid Renewed Banking Concerns And Contagion Fears
Renewed concerns about the banking system appear to weigh on stocks, as the major index futures point to a sharply lower opening on Friday. 
Via Benzinga
Why Are Stocks Up Today?
Stocks are up today as investors react to the latest news from the Federal Reverse concerning a new interest rate increase. 
Via InvestorPlace
< Previous 1 2
...
17 18 19 20 21 22 23 24 25
...
42 43 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.